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An increased frequency of kidney rejection has been 
reported in diabetic patients who have simultaneous 
pancreas and kidney transplantation compared with pa-
tients who have a kidney transplant alone. Kidney graft 
outcome is similar in the two groups. The mechanism 
for increased kidney graft rejection with a simultaneous 
pancreas graft is not clear. It is ascribed to the immu-
nogenicity of the exocrine pancreas that initiates migra-
tion of activated cells from the peripheral blood that are 
entrapped in the kidney. Since the volume of the trans-
planted tissue is less in islet transplantation (usually <2 
ml) than in pancreas transplantation, one might not 
expect an increased frequency of kidney rejection in 
islet cell recipients. We looked at biopsy-proven kidney 
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rejection episodes in patients who had combined kidney 
and islet transplants and compared this with the fre-
quency of rejection in diabetic and nondiabetic patients 
who underwent a kidney transplant alone under the 
same immunosuppression. Diabetic patients who had 
kidney islet transplants (n=9) had a higher frequency 
of rejection (100%) compared with diabetic patients 
(n=107, 55.1 %) and nondiabetic patients (n=327, 65%) 
who had a kidney transplant alone. The I-year graft 
and patient survival rates were not different among the 
groups. Although the number of patients is small, it 
would appear that transplantation of a low volume of 
islet cells with high purity can lead to an increased 
frequency of kidney rejection. This is unlikely to be 
explained solely on the basis of fewer antigen matches 
in these recipients but may reflect the inherent immu-
nogenicity of the purified islet preparations. Alterna-
tively, there may be an effect of their direct infusion 
into the portal vein. 
When a normal kidney is transplanted into a diabetic patient 
with abnormal glucose metabolism, characteristic changes in-
duced by diabetes occur in the transplanted kidney over a 
variable period, sometimes faster than the time of onset noted 
in native kidneys (1). This consequence can be avoided if a 
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successful pancreas transplant is ~erformed restoring eugly- (18) and purified by centrifugation on discontinuous density gradients 
cemia (2, 3). It has been reported that there is no overall (Eurocollins-Ficoll, density=1.l08, 1.096, 1.037) using a Cobe 2991 cell 
adverse effect of performing pancreas transplant on the out- separator (Cobe, Lakewood, CO) (19, 20). Immediately after renal 
come of the patient or the transplant kidney (4,5). With the transplantation, an upper midline incision was performed and a 16-
increasing success of pancreas transplantation, this approach gauge catheter was placed in a jejunal vein for islet infusion. In one 
patient (No.3) the catheter was left in place for transplantation of is increasingly accepted as the closest approximation of the islets from a third-party donor. 
ideal of long-term restoration of normal metabolism. While the Patient 5 received islets via the transhepatic route from a third-
long-term kidney graft outcome is similar in diabetic patients party donor, since islets of sufficient quality could not be obtained from 
undergoing combined pancreas and kidney grafts, there are the pancreas of the kidney donor. The trans hepatic route was also used 
many series that show an increased frequency of acute kidney to transplant islets from a second donor in patient 8. Islets were all 
rejection episodes in this group of patients (6-8). This has not transplanted fresh or after overnight culture at room temperature. 
been noted in all series (9, 10). The mechanism of how the Immunosuppression. All patients received a 100-mg bolus of meth· 
pancreas graft might induce rejection in the transplanted kid- ylprednisolone during the operation, followed by a decreasing predni-
ney is not known; however, on the basis of experimental evi- sone dose from 200 mg to 20 mg over the course of the first week 
dence it has been proposed that activated cells from the circu- posttransplant. FK506 was given at a dose of 0.1 mg/kg intravenously 
administered as a continuous infusion over 24 hr, beginning immedi-
lation migrate and lodge in the transplanted kidney (11). ately following the transplantation. When patients resumed a solid 
While this is controversial, exocrine tissue probably contrib- diet, an oral dose of 0,15 mg/kg/bid was started. Patients 6-8 also 
utes significantly to the immunogenicity of islet preparations received Imuran 200 mgjday during the first postoperative week in 
(12-16). Since the volume of nonislet cells is much lower with addition to the previously mentioned immunosuppression. 
an islet graft than with a whole pancreas graft, an increased Definition of rejection. Kidney biopsy was performed to confirm a 
frequency of kidney rejection might not be expected in patients clinical impression of rejection, and the tissue was processed immedi-
undergoing islet transplantation. It was therefore of interest to ately in formalin and stained with hematoxylin and eosin, Jones, 
examine the frequency of kidney rejection episodes in patients trichrome, and PAS stains. The only rejection episodes considered in 
who underwent combined kidney and purified islet transplan- this report were those confirmed histologically by biopsy. Rejection 
tation. episodes were graded as mild, moderate, or severe as follows. Mild acute 
cellular rejection was considered as: small aggregates of mononuclear 
MATERIALS AND METHODS cells with evidence of tubulitis. Moderate: same as above with some 
Patient characteristics. Eight patients aged 29-38 years with long-
standing insulin-dependent (type 1) diabetes mellitus as evidenced by 
an absent C-peptide response to either glucagon or Sustacal stimulation 
received 9 combined cadaveric kidney-islet grafts (one retransplant), 
with one (n=6), two (n=2), or three (n=l) islet donors. The cadaveric 
donor ABO types were all compatible with recipient types and HLA 
matching was random, the antigen match being 0-2 for the kidney and 
0-3 for islets (Table 1). All patients had a negative crossmatch. One 
patient who underwent the procedure died on the fifth postoperative 
day of aspiration pneumonia and did not have rejection until this time. 
This patient was not included in the analysis of frequency of rejection, 
but was included in the calculation of mortality and graft survival. 
Islet isolation and transplantation, Human islets were obtained by a 
modification (17) of the automated method for human islet isolation 
TABLE 1. Characteristics of diabetic patients who underwent 
combined kidney-islet transplantation 
Duration 
Patient Age Sex of Procedure" HLA matches No. diabetes 
mellitus 
1 38 M 22 KI A2 
2 29 M 23 KI+I Donor 1 (KI): DRl:DR4 
Donor 2 (1): DR4 
KI Donor 3 (Kl): B7 
3 34 M 26 KI+I, I Donor 1 (K1): A2 
Donor 2 0): A2, B8, DR3 
Donor 3 (I): A2, B8, DR3 
4 36 F 15 KI None 
5 36 M 17 K,I Donor 1 (K): none 
Donor 2 (1): DR3 
6 32 M 18 KI None 
7 32 M 22 KI None 
8 29 M 16 KI,I Donor 1 (Kl): A2, B62 
Donor 2 (I): A2, DR4 
°KI: simultaneous kidney + islets. KI+I: simultaneous kidney + 
islets + islets from another donor, K,I: kidney with islets from a 
separate donor. 
coalescence of mononuclear aggregates. Severe: same as above with 
evidence of necrosis, interstitial hemorrhage, and acute inflammation 
or vasculitis. 
Statistics. Data were analyzed by chi square test with continuity 
correction. Significance of difference was considered as P < 0.05. 
RESULTS 
Six-month graft survival was 86%,76%, and 78% in diabetic 
recipients of a solitary kidney graft (DK),* nondiabetic kidney 
transplant recipients (NDK), and diabetic recipients of kidney 
and islets (DKI), respectively (Table 2). One-year graft survival 
was 82% (DK), 73% (NDK), and 78% (DKI). Mortality rates 
were not different in the groups. The unexpected finding was 
the frequency of kidney rejection episodes: 55.1% in DK, 65% 
in NDK, and 100% in DKI patients (P < 0.02). 
The number and grade of biopsy-proven rejection episodes 
and current graft outcome in DKI patients are shown in Table 
3. Most episodes were mild and easily treated with corticoster-
oids. Only one graft was lost to refractory recurrent rejection 
episodes. After rejection episodes, 5 patients still have demon-
strable islet cell function, but all patients still require exogenous 
insulin. The best results were obtained in the patients who 
received islets from more than one donor pancreas. 
In order to examine the rejection frequency in more detail, a 
matched case control study from the original group was done. 
Diabetic (n=9) and nondiabetic (n=9) controls were randomly 
selected for each kidney-islet recipient using matching criteria 
of age, sex, and time of transplant. The frequency of kidney 
rejection episodes was compared between kidney islet patients 
and controls using McNemar's test. Mean and median creati-
nine, FK dose, and FK levels were compared between the groups 
using a one-way repeated measure analysis of variance and 
Friedman's nonparametric test (21). 
* Abbreviations: DK, diabetic kidney recipient; DKI, diabetic kidney 
and islet recipient; NDK, nondiabetic kidney recipient. 
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TABLE 2. Comparison of graft and patient survival and frequency of 
rejection episodes 
Diabetic kidney 
Diabetic Nondiabetic and islet (9 
(n=107) (n=327) kidney grafts, 8 
patients) 
Graft survival (%) 
6 months 86% 76% 78% 
1 year 82% 73% 78% 
I-year mortality 10.3% 6.7% 12.5% 
rate 
Frequency of kidney 55.1% 65% 100%' 
rejection 
, P<0.02 (chi square). 
TABLE 3. Outcome in diabetic patients who underwent kidney-islet 
transplantation 
Patient No. Time Severity Kidney Islet outcome 
no. rejections (days) outcome 
------
1 2 :34,48 Mild Creat.2.0 (+) C-peptide 
2 3 11,65,75 Mild, Graft (+) C-peptide 
mod failed 
3 (2nd Tx) 8. 14, 425 Mild, Creat.1.6 (+) C-peptide 
mod 
3 1 12 Mild Creat.1.9 (+) C-peptide 
4 2 20, 240 Mild, Creat. 1.3 (-) C-peptide 
mod 
5 4 10,40,63, Mild, Creat.2.2 (-) C-peptide 
94 mod 
6 2 10,72 Mild Creat. 2.0 (+) C-peptide 
7 18 Mild Creat. 2.0 (-) C-peptide 
8 105 Mild Creat. 1.8 (+) C-peptide 
Again, the frequency of rejection was higher in DKI recipi-
ents-lOO% vs. 55.6% in DK case controls and 33.3% in NDK 
case controls. The FK dose was 13.3±5.9 mg/day in DKI, 1O.7± 
7.1 mg/day in DK, and 14.0±9.1 mg/day in NDK (P>O.05). 
The FK levels were also similar in the groups: O.6±O.3 ng/ml 
(DKI), O.6±O.6 (DK), and O.S±OA (NDK) (P>O.05). Creatinine 
levels at a similar time point were no different among the 
groups. 
DISCUSSION 
Although the number of patients in our kidney islet group is 
small, the frequency of rejection episodes seems out of propor-
tion to what was expected for islet transplantation. As with the 
rejection episodes seen in patients with kidney and pancreas 
grafts, these rejection episodes are largely manageable, and 
graft and patient outcomes are similar in the groups studied. 
With this small number of patients it was not possible to 
analyze if significant differences in HLA matches were present 
in the three groups. In the recipients of kidney transplant 
alone, 2/3 of the patients had 2-antigen matches or less, similar 
to our patients. 
It has been assumed in whole pancreas transplant that the 
exocrine gland initiates the recipient response and that reactive 
cells migrate to the kidney and possibly provide some protection 
to the pancreas (11). The reactivity to islets was supposed to 
be minimal. 
In light of these data showing an apparent increased fre-
quency of kidney rejection, the immunogenicity of the islet 
preparation and the intravascular route of administration (por-
tal vein) must be considered as possible determining factors. 
Despite the small volume and relative apparent purity of the 
islet preparations, significant numbers of contaminating cells 
are still present. The potentially immunogenic cells include 
acini, ducts, lymphoid, and dendritic cells (22). 
The intravascular administration of antigen and cells may 
facilitate antigen recognition and activate the immune response 
by direct presentation of antigen to circulating recipient lymph-
oid cells. The site of the intravascular antigen and cell admin-
istration may also be a key since in other systems, the portal 
venous route produces different immune responses than sys-
temic venous administration (23). 
Our data also indicate that a single mild rejection episode, 
even in a patient who receives islets from multiple donors, may 
be enough to compromise the ability to achieve complete insulin 
and independence, although diabetes control may be stabilized 
(17). It is therefore critical to develop effective procedures to 
decrease the immunogenicity of islet preparations before trans-
plantation or to explore alternative sites or routes of adminis-
tration. It will be of interest to determine if increased frequency 
of kidney rejection has been observed following transplantation 
of kidney and islets that have been cryopreserved or cultured 
for 1 week at 24 'C. Experimental evidence suggests that these 
procedures may be effective pretransplant treatments to de-
crease islet preparation immunogenicity (24, 25). 
Acknowledgments. The authors acknowledge Dr. Mike Nalesnik for 
review of the biopsies, and the secretarial assistance of Ms. T. Whigham 
and Ms. K. Murray in the preparation of the manuscript. 
REFERENCES 
1. Mauer SM, Goetz FC, McHugh LE, et al. Long term study of 
normal kidneys transplanted into patients with type I diabetes. 
Diabetes 1989; 38: .516. 
2. Bohman S-O, Tyden G, Wilczek H, et al. Prevention of kidney 
Diabetes 1985; 34: 306. 
3 Bilous RW, Mauer SM, Sutherland DER, et al. The effects of 
pancreas transplantation on the glomerular structure of renal 
allografts in patients with insulin-dependent diabetes. N Engl J 
Med 1988; 321: 80. 
4. Nakache R, Mainette L, Tyden G, Groth CG. Renal transplanta-
tion in diabetes mellitus: influence of combined pancreas-kidney 
transplantation on outcome. Transplant Proc 1990; 22: 624. 
5. Sollinger HW, Knechtle SJ, Reed A, et al. Experience with 100 
consecutive simultaneous kidney pancreas transplants with blad-
der drainage. Ann Surg 1991; 214: 703. 
6. Hopt UT, Busing M, Schareck W, Muller GH. Differential immu-
nostimulatory properties of combined pancreas-kidney and sin-
gle-kidney allografts. Diabetes 1989; 38 (suppl): 251. 
7. Richards KF, Belnap LeG P, Rees WV, Stevens LE. Increased 
incidence of kidney rejection episodes in patients receiving com-
bined kidney-pancreas transplant. Diabetes 1989; 38 (supp!): 251. 
8. Gruessner RWG, Dunn DL, Tzardis PJ, et al. Simultaneous pan-
creas and kidney transplants versus single kidney transplants 
and previous kidney transplants in uremic patients and single 
pancreas transplants in non uremic diabetic patients: comparison 
of rejection, morbidity, and long-term outcome. Transplant Proc 
1990; 22: 622. 
9. Cantarovich D, Paineau J, Hourmant M, et al. Low incidence of 
rejection following combined kidney and pancreas transplanta-
tion. Transplant Proc 1990; 22: 626. 
10. Secchi A, Di Carlo V, Martinenghi S, et al. Effect of pancreas 
transplantation on life expectancy, kidney function and quality 
of life in uraemic type I (insulin-dependent) diabetic patients. 
Diabetologia 1991; 34: S141. 
11. Flaa C, Rabinovitch A, Mintz D, Miller J. Early detection of 
pancreatic allograft rejection in dogs: immunologic and physio-
764 TRANSPLANTATION Vol. 55, No.4 
logic monitoring in simultaneous kidney and pancreas transplan-
tation and response in immunosuppression. World J Surg 1981; 
5: 430. 
12. Gores PF, Majoral J, Field MJ, Sutherland DER. Comparison of 
the immunogenicity of purified and unpurified murine islet al-
lografts. Transplantation 1980; 41: 529. 
13. Gotoh M, Maki T, Porter J, Satoni S, Monaco AP. Effect of 
contaminating lymph nodes, ductal and vascular tissue, and 
exocrine tissue on the survival of purified pancreatic islet allo-
grafts. Transplant Proc 1986; 18: 1848. 
14. Gray DWR, Sutton R, McShane P, Peters M, Morris PJ. Exocrine 
contamination impairs implantation of pancreatic islets trans-
planted beneath the kidney capsule. J Surg Res 1988; 45: 432. 
15. Gotoh M, PorterJ, Kanai T, Monaco AP, Maki T. Effect of specific 
and nonspecific alloantigen stimulation on islet allograft sur-
vival. Transplant Proc 1989; 21: 2746. 
16. Gray DWR. The role of exocrine tissue in pancreatic islet trans-
plantation. Transplant Int 1989; 2: 41. 
17. Ricordi C, Tzakis AG, Carroll PB, et al. Human islet isolation and 
allotransplantation in 22 consecutive cases. Transplantation 
1992; 53: 407. 
18. Ricordi C, Lacy PE, Finke EH, Olack B, Scharp DW. An automated 
method for the isolation of human pancreatic islets. Diabetes 
1988; 37: 413. 
19. Lake SP, Basset PD, Larkins A, et al. Large scale purification of 
human islets utilizing discontinuous albumin gradient on IBM 
2991 cell separator. Diabetes 1989; 38 (suppl): 143. 
20. Alejandro R, Strasser S, Zuker PF, Mintz DH. Isolation of pan-
creatic islets from dogs: semiautomated purification on albumin 
gradients. Transplantation 1990; 50: 207. 
21. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. 
New York: Wiley, 1981. 
22. Sever CE, Demetris A,J, Zeng J, et al. Composition of human islet 
cell preparations for transplantation. Acta Diabetol 1992; 28: 
233. 
23. Triger DR, Cynamon MH, Wright R. Studies on hepatic uptake of 
antigen: I. Comparison of inferior vena cava and portal vein 
routes of immunization. Immunology 1973; 25: 941. 
24. Warnock GL, Knetman NM, Ryan E, et al. Normoglycemia after 
transplantation of freshly isolated and cryopreserved pancreatic 
islets in type 1 (insulin-dependent) diabetes mellitus. Diabeto-
logia 1991; 34: 55. 
25. Scharp DW, Lacy PE, Finke E, Olack B. Low-temperature culture 
of human islets isolated by the distention method and purified 
with Ficoll or Percoll gradients. Surgery 1987; 102: 869. 
Received 8 June 1992. 
Accepted 13 August 1992. 
PAPER NO. B-4 BY PATRICIA B. CARROLL, M.D. 
PITTSBURG H, PENNSYLVANIA 
DISCUSSION 
DR. BRAYMAN (Philadelphia, Pennsylvania): Was the de-
gree of HLA matching in the kidney transplant alone group, 
diabetic and nondiabetic, similar to the islet group? 
DR. CARROLL: It is not possible to do statistics on the 
small number of patients that we had in the islet group, but 
two-thirds of the patients in the other two groups had zero to 
two antigen matches. That means that some patients had better 
matches, but most were similar to the patients who had kidney 
islet grafts. 
DR. BRAYMAN: Could you comment about the severity of 
the rejection episodes in the kidney transplant alone versus the 
kidney islet group, do you have any idea whether they were 
similar or different? 
DR. CARROLL: I think our patient numbers are still too 
small for conclusions. The whole spectrum is seen in the other 
groups also. 
DR. BRAYMAN: Finally, since most rejection episodes oc-
curred within the first three weeks after transplantation, would 
you comment on whether or not you think that an induction 
therapy with ALG or one of the monoclonals may be worth-
while? 
DR. CARROLL: We have elected not to do that based on 
the transplant team's previous experience. Also, other groups 
involved in islet cell transplantation have been using induction 
therapy; the major problem that all of the groups currently face 
is rejection of the islet graft. This doesn't seem to be controlled 
by induction therapy. We're really focusing on efforts to alter 
immunogenicity of the islets rather than treating the patients 
with pharmacologic agents. 
DR. RICORDI (Pittsburgh, Pennsylvania): Maybe we can 
learn something from the pancreas transplant experience in 
which the induction therapy with ALG has been used. An 
increased frequency of kidney rejection episodes were observed 
in most of the series. It is interesting to note that the only two 
series that did not report an increased frequency of kidney 
rejection after pancreas transplantation were those using duct 
occlusion techniques. 
DR. BOUDREAUX (New Orleans, Louisiana): Did you find 
any depression of C-peptide levels or any other indication that 
something was happening to your islet grafts at the times of 
these kidney graft rejections? 
DR. CARROLL: None of our patients have had rejection of 
islet independent of kidney rejection. The C-peptide drops 
when kidney rejection is occurring. And we have seen that with 
recycling of steroids, you can observe some recovery of function. 
But we have never seen a patient achieve insulin independence, 
even with one mild rejection episode. 
DR. BOUDREAUX: Did you find a "stair-stepping" decline 
in islet function? 
DR. CARROLL: Yes. 
DR. GORES (Minneapolis, Minnesota): At the University of 
Minnesota between 1978 and 1991, we performed a dozen 
simultaneous islet/kidney transplants using our standard im-
munosuppression for cadaver kidney recipients, which included 
ALG; we didn't have any success with the islet grafts as far as 
achieving insulin independence. There was a 55 percent expe-
rience with acute renal rejection episodes, and that was not 
different than diabetic recipients of kidney transplants alone 
from cadaveric donors. 
DR. CARROLL: It might be patient selection. I don't really 
know. The other variables would be, did you use one donor? 
DR. GORES: We used one donor, and likely there was more 
exocrine tissue than in your series, but we used ALG induction, 
not just FK506 and prednisone. Perhaps that at least partially 
explains the difference. 
DR. CARROLL: But the pancreas transplant people who use 
the same induction see the increased frequency of kidney 
rejection. You have reported it and other groups have reported 
it. 
DR. GORES: The pancreas, but I'm talking about islets. 
DR. CARROLL: Right. 
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DR. GORES: Using the same immunosuppression that Dr. 
Sullivan uses for the pancreas. 
DR. CARROLL: It's interesting. Thank you. 
DR. SUTHERLAND (Minneapolis, Minnesota): Your ex-
perience with renal rejection episodes in islet/kidney transplant 
recipients is similar to the experience with the pancreas/kidney 
transplants. You added islets without increasing intensity of 
induction immunosuppression with ALG or OKT3, and an 
extremely high incidence of rejection resulted. Indeed, the 
incidence of 100% is higher than with simultaneous pancreas/ 
kidney transplants. I wonder if the purity of your islet prepa-
rations is less than you think. There may be sufficient contam-
ination with lymphatic tissue so that the passenger leukocyte 
load to which the recipient is exposed is significantly increased 
over that associated with a kidney transplant alone. 
One statement you made, that exocrine tissue is more im-
munogenic than islets, is not supported by experimental evi-
dence. In some experimental transplant models, "dirty" islets 
have been associated with a higher frequency or more rapid 
rejection than pure islets. However, in most of these experi-
ments, the "dirty" islets have included lymphatic and vascular 
tissue. Dr. Gores, who just commented, reported an experiment 
several years ago in which he deliberately added back exocrine 
tissue to the islet preparation, without the lymphatic or vas-
cular or ductal tissue. When such tissue was transplanted, there 
was no increase in frequency or intensity of rejection over that 
observed when pure islets were transplanted, indicating that 
exocrine tissue itself did not increase immunogenicity. Dr. 
Monaco's laboratory has reported an increase in immunogenic-
ity when impure islets are transplanted, but again the islet 
tissue was contaminated by lymphatic, vascular, and ductal 
tissue as well as exocrine tissue. When a whole pancreas is 
transplanted, the maximal load of exocrine tissue possible is 
transplanted, but the graft is also very contaminated with 
lymphatic tissue. In fact, a pancreas graft can actually induce 
graft versus host disease to some degree, particularly when a 
graft from a blood group 0 donor is transplanted to a non-O 
recipient, with induction of Coombs' positive hemolytic anemia. 
This has also been seen with other extrarenal organ transplants 
such as a liver, again an organ that harbors a large amount of 
lymphatic tissue. I think that a fair amount of lymphatic tissue 
also contaminates your islet preparation, and that is why inci-
dence of rejection episodes is similar to what is seen with 
pancreas/kidney transplants. 
DR. CARROLL: We have recently reported with Dr. Deme-
tris and Dr. Sever, that the preparations contain ductal ele-
ments, dendritic cells, lymphoid tissue and much more than 
you would suspect. But it's still amazing that you can inject 
800 microliters of a fairly pure preparation and get the same 
outcome as having a vascularized graft. 
DR. SUTHERLAND: I agree. 
DR. MONACO (Boston, Massachusetts): Well, I can't speak 
for the human, but in the mouse the evidence is overwhelming 
that exocrine tissue subtracted from a crude islet preparation 
is much more immunogenic than the purified islet preparation 
alone. If you hand-pick the islets, they survive longer than if 
you don't, furthermore, hand-picked islets are placed under one 
kidney capsule, and if you place the material remaining in the 
Petri dish under the other kidney capsule, the islets reject. 
DR. CARROLL: I agree with you. 
